| Literature DB >> 27509184 |
Ying-Shan Han1, Narsimha Reddy Penthala2, Maureen Oliveira1, Thibault Mesplède1, Hongtao Xu1, Yudong Quan1, Peter A Crooks2, Mark A Wainberg1.
Abstract
Dengue virus (DENV) causes a variety of difficult-to-treat diseases that threaten almost half of the world's population. Currently, no effective vaccine or antiviral therapy is available. We have examined a series of synthetic resveratrol analogs to identify potential anti-DENV agents. Here, we demonstrate that two resveratrol analogs, PNR-4-44 and PNR-5-02, possess potent anti-DENV activity with EC50 values in the low nanomolar range. These two resveratrol analogs were shown to mainly target viral RNA translation and viral replication, but PNR-5-02 is also likely to target cellular factors inside host cells. Although the precise molecular mechanism(s) mediating anti-DENV activities have not been elucidated, further structure-guided design might lead to the development of newer improved resveratrol derivatives that might have therapeutic value. J. Med. Virol. 89:397-407, 2017.Entities:
Keywords: dengue; inhibitors; resveratrol
Mesh:
Substances:
Year: 2016 PMID: 27509184 DOI: 10.1002/jmv.24660
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 2.327